stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.63
0.21
+2.23%
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) Price to free cash flow
Telix Pharmaceuticals Limited has no meaningful price to free cash flow: its trailing twelve-month free cash flow is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| VKTX Viking Therapeutics, Inc. compare | n/m |
| TLX Telix Pharmaceuticals Limited | n/m |
| DNLI Denali Therapeutics Inc. compare | n/m |
| CELC Celcuity, Inc. compare | n/m |
| VRDN Viridian Therapeutics, Inc. compare | n/m |
| IDYA IDEAYA Biosciences, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| TARS Tarsus Pharmaceuticals, Inc. compare | 134× |
| Biotechnology industry median | 24.8× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))